Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fink, D.
Right arrow Articles by Howell, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fink, D.
Right arrow Articles by Howell, S. B.

Clinical Cancer Research, Vol 4, Issue 1 1-6, Copyright © 1998 by American Association for Cancer Research

ARTICLES

The role of DNA mismatch repair in drug resistance

D Fink, S Aebi and SB Howell
Department of Medicine, University of California at San Diego, La Jolla 92093-0058, USA.

Loss of DNA mismatch repair (MMR) has been observed in a variety of human cancers. In addition to predisposing to oncogenesis, loss of MMR activity is of concern with respect to the use of chemotherapeutic agents to treat established tumors. Loss of MMR results in drug resistance directly by impairing the ability of the cell to detect DNA damage and activate apoptosis and indirectly by increasing the mutation rate throughout the genome. The MMR proteins are involved in mediating the activation of cell cycle checkpoints and apoptosis in response to DNA damage. MMR-deficient cells have been reported to be resistant to the methylating agents procarbazine and temozolomide, the alkylating agent busulfan, the platinum-containing drugs cisplatin and carboplatin, the antimetabolite 6-thioguanine, and the topoisomerase II inhibitors etoposide and doxorubicin. In the case of cisplatin, busulfan, temozolomide, and procarbazine, the degree of resistance has been shown to be sufficient to produce a large difference in clinical responsiveness in vivo in tumor model systems. The available preclinical data suggest that tumors that contain a significant fraction of cells deficient in MMR will demonstrate reduced responsiveness to specific drugs. The challenge now is to assess the clinical significance of the presence of deficient cells in tumors and to discover drugs that retain activity against MMR-deficient cells.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
R. Rodriguez, L. T. Hansen, G. Phear, J. Scorah, M. Spang-Thomsen, A. Cox, T. Helleday, and M. Meuth
Thymidine Selectively Enhances Growth Suppressive Effects of Camptothecin/Irinotecan in MSI+ Cells and Tumors Containing a Mutation of MRE11
Clin. Cancer Res., September 1, 2008; 14(17): 5476 - 5483.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Yamauchi, M. Ogawa, and T. Ueda
Carmustine-Resistant Cancer Cells Are Sensitized to Temozolomide As A Result of Enhanced Mismatch Repair during the Development of Carmustine Resistance
Mol. Pharmacol., July 1, 2008; 74(1): 82 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Sarkaria, G. J. Kitange, C. D. James, R. Plummer, H. Calvert, M. Weller, and W. Wick
Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
Clin. Cancer Res., May 15, 2008; 14(10): 2900 - 2908.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Zeng and T. J. Kinsella
Mammalian Target of Rapamycin and S6 Kinase 1 Positively Regulate 6-thioguanine-Induced Autophagy
Cancer Res., April 1, 2008; 68(7): 2384 - 2390.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Song, I.-m. Shih, R. Salani, D. W. Chan, and Z. Zhang
Annexin XI Is Associated with Cisplatin Resistance and Related to Tumor Recurrence in Ovarian Cancer Patients
Clin. Cancer Res., November 15, 2007; 13(22): 6842 - 6849.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Fontijn, A. D. Adema, K. K. Bhakat, H. M. Pinedo, G. J. Peters, and E. Boven
O6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells
Mol. Cancer Ther., October 1, 2007; 6(10): 2807 - 2815.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. A. Flanagan, B. W. Robinson, C. M. Krokosky, and D. S. Shewach
Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers
Mol. Cancer Ther., June 1, 2007; 6(6): 1858 - 1868.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. R. Hart, O. Glebov, R. J. Ernst, I. R. Kirsch, and J. K. Barton
DNA mismatch-specific targeting and hypersensitivity of mismatch-repair-deficient cells to bulky rhodium(III) intercalators
PNAS, October 17, 2006; 103(42): 15359 - 15363.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. D. Kennedy and A. D. D'Andrea
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
J. Clin. Oncol., August 10, 2006; 24(23): 3799 - 3808.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Lanza, R. Gafa, A. Santini, I. Maestri, L. Guerzoni, and L. Cavazzini
Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients
J. Clin. Oncol., May 20, 2006; 24(15): 2359 - 2367.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. A. Sinicrope, R. L. Rego, K. C. Halling, N. R. Foster, D. J. Sargent, B. La Plant, A. J. French, C. J. Allegra, J. A. Laurie, R. M. Goldberg, et al.
Thymidylate synthase expression in colon carcinomas with microsatellite instability.
Clin. Cancer Res., May 1, 2006; 12(9): 2738 - 2744.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Hunter, R. Smith, D. P. Cahill, P. Stephens, C. Stevens, J. Teague, C. Greenman, S. Edkins, G. Bignell, H. Davies, et al.
A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy.
Cancer Res., April 15, 2006; 66(8): 3987 - 3991.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Peters, J. Freund, and R. L. Ochs
Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells
Mol. Cancer Ther., October 1, 2005; 4(10): 1605 - 1616.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. R. Plummer, M. R. Middleton, C. Jones, A. Olsen, I. Hickson, P. McHugh, G. P. Margison, G. McGown, M. Thorncroft, A. J. Watson, et al.
Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1
Clin. Cancer Res., May 1, 2005; 11(9): 3402 - 3409.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Fukushima, Y. Katayama, T. Watanabe, A. Yoshino, A. Ogino, T. Ohta, and C. Komine
Promoter Hypermethylation of Mismatch Repair Gene hMLH1 Predicts the Clinical Response of Malignant Astrocytomas to Nitrosourea
Clin. Cancer Res., February 15, 2005; 11(4): 1539 - 1544.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
I.-S. Song, N. Savaraj, Z. H. Siddik, P. Liu, Y. Wei, C. J. Wu, and M. T. Kuo
Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells
Mol. Cancer Ther., December 1, 2004; 3(12): 1543 - 1549.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Yan, A. B. Desai, J. W. Jacobberger, R. M. Sramkoski, T. Loh, and T. J. Kinsella
CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses
Mol. Cancer Ther., September 1, 2004; 3(9): 1147 - 1157.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-R. Li, E. I. Shagisultanova, K. Yamashita, Z. Piao, M. Perucho, and S. R. Malkhosyan
Hypersensitivity of Tumor Cell Lines with Microsatellite Instability to DNA Double Strand Break Producing Chemotherapeutic Agent Bleomycin
Cancer Res., July 15, 2004; 64(14): 4760 - 4767.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
P. Morales-Ramirez, T. Vallarino-Kelly, V. L. Cruz-Vallejo, R. Lopez-Iturbe, and H. Alvaro-Delgadillo
In vivo kinetics of micronuclei induction by bifunctional alkylating antineoplastics
Mutagenesis, May 1, 2004; 19(3): 207 - 213.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
V. A. Barvaux, M. Ranson, R. Brown, R. S. McElhinney, T. B. H. McMurry, and G. P. Margison
Dual repair modulation reverses Temozolomide resistance in vitro
Mol. Cancer Ther., February 1, 2004; 3(2): 123 - 127.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
I. Gaudreault, D. Guay, and M. Lebel
YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins
Nucleic Acids Res., January 12, 2004; 32(1): 316 - 327.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Cortellino, D. Turner, V. Masciullo, F. Schepis, D. Albino, R. Daniel, A. M. Skalka, N. J. Meropol, C. Alberti, L. Larue, et al.
From The Cover: The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity
PNAS, December 9, 2003; 100(25): 15071 - 15076.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Mita, E. Chatelut, M. Bekradda, P. Soulie, P. Canal, J.-L. Misset, E. Cvitkovic, and R. Bugat
Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies
Ann. Onc., December 1, 2003; 14(12): 1776 - 1782.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Samimi, N. M. Varki, S. Wilczynski, R. Safaei, D. S. Alberts, and S. B. Howell
Increase in Expression of the Copper Transporter ATP7A during Platinum Drug-Based Treatment Is Associated with Poor Survival in Ovarian Cancer Patients
Clin. Cancer Res., December 1, 2003; 9(16): 5853 - 5859.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. W. Robinson, M. M. Im, M. Ljungman, F. Praz, and D. S. Shewach
Enhanced Radiosensitization with Gemcitabine in Mismatch Repair-Deficient HCT116 Cells
Cancer Res., October 15, 2003; 63(20): 6935 - 6941.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kishi, Y. Doki, M. Yano, T. Yasuda, Y. Fujiwara, S. Takiguchi, S. Kim, I. Higuchi, and M. Monden
Reduced MLH1 Expression after Chemotherapy Is an Indicator for Poor Prognosis in Esophageal Cancers
Clin. Cancer Res., October 1, 2003; 9(12): 4368 - 4375.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Fallik, F. Borrini, V. Boige, J. Viguier, S. Jacob, C. Miquel, J.-C. Sabourin, M. Ducreux, and F. Praz
Microsatellite Instability Is a Predictive Factor of the Tumor Response to Irinotecan in Patients with Advanced Colorectal Cancer
Cancer Res., September 15, 2003; 63(18): 5738 - 5744.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
N. F. Krynetskaia, T. L. Brenner, E. Y. Krynetski, W. Du, J. C. Panetta, P. Ching-Hon, and W. E. Evans
Msh2 Deficiency Attenuates But Does Not Abolish Thiopurine Hematopoietic Toxicity in Msh2-/- Mice
Mol. Pharmacol., August 1, 2003; 64(2): 456 - 465.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. M. Ribic, D. J. Sargent, M. J. Moore, S. N. Thibodeau, A. J. French, R. M. Goldberg, S. R. Hamilton, P. Laurent-Puig, R. Gryfe, L. E. Shepherd, et al.
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
N. Engl. J. Med., July 17, 2003; 349(3): 247 - 257.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
K. R. Brooks, K. To, M.-B. M. Joshi, D. H. Conlon, J. E. Herndon II, T. A. D'Amico, and D. H. Harpole Jr
Measurement of chemoresistance markers in patients with stage iii non-small cell lung cancer: a novel approach for patient selection
Ann. Thorac. Surg., July 1, 2003; 76(1): 187 - 193.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Yan, S. E. Berry, A. B. Desai, and T. J. Kinsella
DNA Mismatch Repair (MMR) Mediates 6-Thioguanine Genotoxicity by Introducing Single-strand Breaks to Signal a G2-M Arrest in MMR-proficient RKO Cells
Clin. Cancer Res., June 1, 2003; 9(6): 2327 - 2334.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Fourrier, P. Brooks, and J.-M. Malinge
Binding Discrimination of MutS to a Set of Lesions and Compound Lesions (Base Damage and Mismatch) Reveals Its Potential Role as a Cisplatin-damaged DNA Sensing Protein
J. Biol. Chem., May 30, 2003; 278(23): 21267 - 21275.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Peltomaki
Role of DNA Mismatch Repair Defects in the Pathogenesis of Human Cancer
J. Clin. Oncol., March 15, 2003; 21(6): 1174 - 1179.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Pepponi, G. Marra, M. P. Fuggetta, S. Falcinelli, E. Pagani, E. Bonmassar, J. Jiricny, and S. D'Atri
The Effect of O6-Alkylguanine-DNA Alkyltransferase and Mismatch Repair Activities on the Sensitivity of Human Melanoma Cells to Temozolomide, 1,3-bis(2-Chloroethyl)1-nitrosourea, and Cisplatin
J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 661 - 668.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Petit, D. J. Bearss, D. A. Troyer, R. M. Munoz, and J. J. Windle
p53-independent Response to Cisplatin and Oxaliplatin in MMTV-ras Mouse Salivary Tumors
Mol. Cancer Ther., February 1, 2003; 2(2): 165 - 171.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Katano, A. Kondo, R. Safaei, A. Holzer, G. Samimi, M. Mishima, Y.-M. Kuo, M. Rochdi, and S. B. Howell
Acquisition of Resistance to Cisplatin Is Accompanied by Changes in the Cellular Pharmacology of Copper
Cancer Res., November 15, 2002; 62(22): 6559 - 6565.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Wittig, M. Nessling, R. D. Will, J. Mollenhauer, R. Salowsky, E. Munstermann, M. Schick, H. Helmbach, B. Gschwendt, B. Korn, et al.
Candidate Genes for Cross-Resistance against DNA-damaging Drugs
Cancer Res., November 15, 2002; 62(22): 6698 - 6705.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
R. J. Mitchell, S. M. Farrington, M. G. Dunlop, and H. Campbell
Mismatch Repair Genes hMLH1 and hMSH2 and Colorectal Cancer: A HuGE Review
Am. J. Epidemiol., November 15, 2002; 156(10): 885 - 902.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
X. Lin, T. Okuda, A. Holzer, and S. B. Howell
The Copper Transporter CTR1 Regulates Cisplatin Uptake in Saccharomyces cerevisiae
Mol. Pharmacol., November 1, 2002; 62(5): 1154 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. M. d. l. Alas, G. Los, X. Lin, B. Kurdi-Haidar, G. Manorek, and S. B. Howell
Identification of Transdominant-Negative Genetic Suppressor Elements Derived from hMSH2 That Mediate Resistance to 6-Thioguanine
Mol. Pharmacol., November 1, 2002; 62(5): 1198 - 1206.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Mohindra, L. E. Hays, E. N. Phillips, B. D. Preston, T. Helleday, and M. Meuth
Defects in homologous recombination repair in mismatch-repair-deficient tumour cell lines
Hum. Mol. Genet., September 1, 2002; 11(18): 2189 - 2200.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
R. Miturski, M. Bogusiewicz, C. Ciotta, M. Bignami, M. Gogacz, and D. Burnouf
Mismatch Repair Genes and Microsatellite Instability as Molecular Markers for Gynecological Cancer Detection
Experimental Biology and Medicine, September 1, 2002; 227(8): 579 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Liu, S. Schwartz, B. M. Davis, and S. L. Gerson
Chemotherapy-induced O6-Benzylguanine-resistant Alkyltransferase Mutations in Mismatch-deficient Colon Cancer
Cancer Res., June 1, 2002; 62(11): 3070 - 3076.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. B. Deng, H. K. Parekh, K.-C. Chow, and H. Simpkins
Increased Expression of Dihydrodiol Dehydrogenase Induces Resistance to Cisplatin in Human Ovarian Carcinoma Cells
J. Biol. Chem., April 19, 2002; 277(17): 15035 - 15043.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. M. Lindor, L. J. Burgart, O. Leontovich, R. M. Goldberg, J. M. Cunningham, D. J. Sargent, C. Walsh-Vockley, G. M. Petersen, M. D. Walsh, B. A. Leggett, et al.
Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors
J. Clin. Oncol., February 15, 2002; 20(4): 1043 - 1048.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
E. D. Larson, D. Nickens, and J. T. Drummond
Construction and characterization of mismatch-containing circular DNA molecules competent for assessment of nick-directed human mismatch repair in vitro
Nucleic Acids Res., February 1, 2002; 30(3): e14 - e14.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
P. Karran
Mechanisms of tolerance to DNA damaging therapeutic drugs
Carcinogenesis, December 1, 2001; 22(12): 1931 - 1937.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
H. Niedner, R. Christen, X. Lin, A. Kondo, and S. B. Howell
Identification of Genes That Mediate Sensitivity to Cisplatin
Mol. Pharmacol., December 1, 2001; 60(6): 1153 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Pepponi, G. Graziani, S. Falcinelli, P. Vernole, L. Levati, P. M. Lacal, E. Pagani, E. Bonmassar, J. Jiricny, and S. D'Atri
hMSH3 overexpression and cellular response to cytotoxic anticancer agents
Carcinogenesis, August 1, 2001; 22(8): 1131 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
R Ward, A Meagher, I Tomlinson, T O'Connor, M Norrie, R Wu, and N Hawkins
Microsatellite instability and the clinicopathological features of sporadic colorectal cancer
Gut, June 1, 2001; 48(6): 821 - 829.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Marchini, G. Damia, M. Broggini, G. Pennella, M. Ripamonti, A. Marsiglio, and C. Geroni
4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a Novel Anticancer Agent Active against Tumor CellLines with Different Resistance Mechanisms
Cancer Res., March 1, 2001; 61(5): 1991 - 1995.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
D. H. Harpole Jr., M.-B. Moore, J. E. Herndon II, T. Aloia, T. A. D’Amico, T. Sporn, A. Parr, I. Linoila, and C. Allegra
The Prognostic Value of Molecular Marker Analysis in Patients Treated with Trimodality Therapy for Esophageal Cancer
Clin. Cancer Res., March 1, 2001; 7(3): 562 - 569.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
F. Vikhanskaya, S. Marchini, M. Marabese, E. Galliera, and M. Broggini
p73{{alpha}} Overexpression Is Associated with Resistance to Treatment with DNA-damaging Agents in a Human Ovarian Cancer Cell Line
Cancer Res., February 1, 2001; 61(3): 935 - 938.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
X. Lin, K. Ramamurthi, M. Mishima, A. Kondo, R. D. Christen, and S. B. Howell
p53 Modulates the Effect of Loss of DNA Mismatch Repair on the Sensitivity of Human Colon Cancer Cells to the Cytotoxic and Mutagenic Effects of Cisplatin
Cancer Res., February 1, 2001; 61(4): 1508 - 1516.
[Abstract] [Full Text]

Home page
 Mol. Cell. Biol.Home page
L. Haracska, S. Prakash, and L. Prakash
Replication past O6-Methylguanine by Yeast and Human DNA Polymerase eta
Mol. Cell. Biol., November 1, 2000; 20(21): 8001 - 8007.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
J. A. Plumb, G. Strathdee, J. Sludden, S. B. Kaye, and R. Brown
Reversal of Drug Resistance in Human Tumor Xenografts by 2'-Deoxy-5-azacytidine-induced Demethylation of the hMLH1 Gene Promoter
Cancer Res., November 1, 2000; 60(21): 6039 - 6044.
[Abstract] [Full Text]

Home page
 JCOHome page
H. F. A. Vasen
Clinical Diagnosis and Management of Hereditary Colorectal Cancer Syndromes
J. Clin. Oncol., November 1, 2000; 18(90001): 81s - 92.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
W. K. Hansen and M. R. Kelley
Review of Mammalian DNA Repair and Translational Implications
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 1 - 9.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. E. Berry, T. W. Davis, J. E. Schupp, H.-S. Hwang, Niels de Wind, and T. J. Kinsella
Selective Radiosensitization of Drug-resistant MutS Homologue-2 (MSH2) Mismatch Repair-deficient Cells by Halogenated Thymidine (dThd) Analogues: Msh2 Mediates dThd Analogue DNA Levels and the Differential Cytotoxicity and Cell Cycle Effects of the dThd Analogues and 6-Thioguanine
Cancer Res., October 1, 2000; 60(20): 5773 - 5780.
[Abstract] [Full Text]

Home page